Editors: Manuela Oliveira, Isa Serrano

Series Title: Frontiers in Antimicrobial Agents

The challenges of antibiotic resistance in the development of new therapeutics

Volume 1

eBook: US $99 Special Offer (PDF + Printed Copy): US $168
Printed Copy: US $119
Library License: US $396
ISSN: 2452-2570 (Print)
ISSN: 2452-2589 (Online)
ISBN: 978-1-68108-141-0 (Print)
ISBN: 978-1-68108-140-3 (Online)
Year of Publication: 2015
DOI: 10.2174/97816810814031150101


The addition of only two novel classes of antibiotics to fight drug resistant microorganisms in the clinic over the past three decades means that the quest for new molecules that are effective against the threat of drug resistance is now a significant issue in modern medicine. Researchers have begun to experiment on alternative therapies to combat this threat.

Novel chemical agents are considered to be drugs of choice for tomorrow's clinical practice owing to their low probability to generate resistance. The first volume of Frontiers in Antimicrobial Agents describes innovative alternatives to the classical antimicrobial therapeutics, such as phage therapy, AMPs, probiotics, novel biocides, natural products and immunotherapy. Cutting-edge research is brought to the forefront, shedding light on the developments taking place to meet the challenge of drug resistant microorganisms. The volume also features information on antimicrobial approaches in veterinary medicine.

The book is a useful reference for researchers, microbiologists and healthcare professionals interested in updates on antibiotic resistance and alternatives to classical antibiotic therapy.


This eBook was conceived after an invitation by the Bentham Science Publishers due to the necessity to review the alternative approaches to the classic antibiotic therapies, and to disperse the shadows over the use of these innovative medicines.

The prevalence of drug-resistant microorganisms has increased worldwide. However, in the last years, few novel entities to fight drug resistant microorganisms have entered the clinic. The antibacterial pipeline is scarce because of the costs associated with the clinical trials and licensing of the antibiotics. Therefore, the quest for alternatives to the classic antimicrobial therapeutics that are effective against drug resistant microorganisms is a timely and very important issue in modern medicine.

The development of novel entities to control the dissemination of drug resistant microorganisms would decrease the morbidity and mortality caused by these disease causing agents, and consequently the economic burden associated with health treatments. Some of these drugs are considered extremely valuable in the nearly future due to their low toxicity, capacity for large scale production, and most importantly their low probability to generate resistance. However, the fear associated to the use of innovative medicines such as phage therapy must be overcome. It will take time to bring phage therapy and other approaches to practice with safety, and to change mentalities of clinicians and the general public. The implementation of such innovative medicines will lead to a decrease in the antimicrobial resistance and related failure treatments. This progress will require contribution of different levels of interdisciplinary knowledge: from researchers to public health entities, from producers to consumers, including politicians.

This eBook aims to contribute to an integrated understanding concerning innovative alternatives to the classical antimicrobial therapeutics. It is based on cutting edge research and the outcome will shed light on the most appropriate approach to control the dissemination of drug resistant microorganisms. It gathers a wide range of topics on the subject and includes several chapters with original material. Authors and co-authors represent a multidisciplinary team that includes scientists and professors with a vast experience in the area, from different universities and research institutions. It is an attempt to encourage the implementation of alternative approaches to the classic antimicrobial therapeutics in human and veterinary health programmes.

The eBook is organized in nine chapters: the general introduction is followed by a review devoted to Phage Therapy, Antimicrobial Peptides (AMPs), Probiotics, Immunotherapy, Natural Compounds, Bacteriocins, Biocides, and lastly to the Novel Therapeutic Strategies in Veterinary Medicine.

Finally, we would like to thank all authors that have enthusiastically contributed to this eBook, and all people that somehow helped us to bring it to daylight, including our family, friends, colleagues and students.

Manuela Oliveira & Isa Serrano
Centro de Investigação Interdisciplinar em Sanidade Animal
Faculdade de Medicina Veterinária, Universidade de Lisboa
Avenida da Universidade Técnica, 1300-477 Lisboa


.Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product.
.COVID 19 – Monitoring with IoT Devices.
.Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents.
.Recent Trends and The Future of Antimicrobial Agents - Part 2.